Black Diamond Therapeutics (BDTX) Current Assets (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported Current Assets for 9 consecutive years, with $115.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 21.35% year-over-year to $115.4 million; the trailing twelve-month figure through Jun 2026 stood at $115.4 million (down 21.35% YoY), and the FY2025 full-year result was $132.4 million, up 30.9% from the prior year.
• Current Assets slipped to $115.4 million in Q2 2026 per BDTX's latest filing, from $123.0 million in the prior quarter.
• Across five years, Current Assets topped out at $188.3 million in Q1 2022 and bottomed at $93.0 million in Q2 2023.
• Historically, Current Assets has averaged $132.9 million across 5 years, with a median of $130.1 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Current Assets sank 44.83% in 2023, then surged 36.31% in 2024.
• Over 5 years, Current Assets stood at $127.7 million in 2022, then advanced by 4.96% to $134.0 million in 2023, then dropped by 24.51% to $101.2 million in 2024, then soared by 30.9% to $132.4 million in 2025, then fell by 12.87% to $115.4 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $115.4 million, $123.0 million, and $132.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.